tert-butyl 4-(2-nitrophenyl)-5,6-dihydropyridine-1(2H)-carboxylate | 494795-55-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 4-(2-nitrophenyl)-5,6-dihydropyridine-1(2H)-carboxylate
• 英文别名: tert-butyl 4-(2-nitrophenyl)-3,6-dihydropyridine-1(2H)-carboxylate；tert-butyl 4-(2-nitrophenyl)-1,2,5,6-tetrahydropyridinecarboxylate；4-(2-nitro-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester；4-(2-Nitrophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester；tert-butyl 4-(2-nitrophenyl)-3,6-dihydro-2H-pyridine-1-carboxylate
• CAS: 494795-55-0
• 化学式: C₁₆H₂₀N₂O₄
• 分子量: 304.346
• InChiKey: OJSOXOBMBMGBBN-UHFFFAOYSA-N

物化性质

• 沸点：
  430.8±45.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  75.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(2-nitrophenyl)-5,6-dihydropyridine-1(2H)-carboxylate 在 palladium on activated charcoal 、 氢气 作用下， 以 乙酸乙酯 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 16.0h， 生成 4-(2-氨基苯基)-哌啶-1-羧酸叔丁酯
  参考文献：
  名称：

  [EN] MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE
  [FR] MODULATEURS DE CANAUX TRPML, LEURS COMPOSITIONS ET PROCÉDÉS D'UTILISATION

  摘要：

  本公开涉及治疗纤毛病的方法，该方法包括向需要治疗的患者施用化合物或其制剂的治疗有效量，其中该化合物调节TRPML离子通道。本公开还涉及公式（III）及其亚式化合物的药物化合物，或其药学上可接受的盐或制剂，以及用于调节TRPML离子通道和治疗疾病的方法。

  公开号：

  WO2022150461A1
• 作为产物：
  描述：

  1-溴-2-硝基苯 、 tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1-(2H)-carboxylate 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以68%的产率得到tert-butyl 4-(2-nitrophenyl)-5,6-dihydropyridine-1(2H)-carboxylate
  参考文献：
  名称：

  [EN] SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1
  [FR] AGONISTES À PETITES MOLÉCULES DU RÉCEPTEUR 1 DE LA NEUROTENSINE

  摘要：

  公开号：

  WO2015200534A3

文献信息

• Substituted piperidines and methods of use
  申请人：——

  公开号：US20040006067A1

  公开（公告）日：2004-01-08

  Selected substituted piperidine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的替代哌啶化合物对预防和治疗疾病，如肥胖等，具有有效性。该发明涵盖了新颖化合物、类似物、前药和其药用可接受盐，以及用于预防和治疗涉及黑素皮质素受体激活的疾病和其他疾病或病症的药物组合物和方法。该发明还涉及制备此类化合物的方法，以及在此类方法中有用的中间体。
• [EN] (4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS DE (4-PHÉNYL-PIPÉRIDIN-1-YL)-[5-1H-PYRAZOL-4-YL)-THIOPHÉN-3-YL]-MÉTHANONE ET LEUR UTILISATION
  申请人：UNIV EDINBURGH

  公开号：WO2011033255A1

  公开（公告）日：2011-03-24

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

  本发明一般涉及治疗化合物领域。更具体地说，本发明涉及某些（4-苯基-哌啶-1-基）-[5-(1 H-吡唑-4-基)-噻吩-3-基]-甲酮化合物，其中包括抑制11β-羟基甾酮脱氢酶1（11β-HSD1）的作用。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在体外和体内抑制11β-羟基甾酮脱氢酶1的用途；治疗通过抑制11β-羟基甾酮脱氢酶1而得到改善的疾病；治疗代谢综合征，其中包括2型糖尿病和肥胖等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质紊乱和缺血性（冠状动脉）心脏病等心血管疾病；治疗轻度认知障碍和早期痴呆等中枢神经系统疾病，包括阿尔茨海默病等。
• Chemical Compounds
  申请人：Maienfisch Peter

  公开号：US20090042938A1

  公开（公告）日：2009-02-12

  The use of a compound of formula (I), Y is a single bond, C═O, C═S or S(O) m where m is 0, 1 or 2; the ring (II) is a 6 membered aromatic ring or is a 5 or 6 membered heteroaromatic ring; Z and Z′ are ═C— or —N— provided that both are not N; R 1 , R 2 R 3 , R 3a , R 4 , R 8 and Ra are specified organic groups and n and p are independently 0, 1, 2, 3 or 4; or salts or N-oxides thereof or compositions containing them in controlling insects, acarines, nematodes or molluscs. Novel compounds are also provided.

  使用化合物公式(I)，其中Y是单键，C═O，C═S或S(O)m，其中m为0，1或2；环(II)是6成员芳香环或是5或6成员杂芳环；Z和Z'是═C—或—N—，但两者都不是N；R1、R2、R3、R3a、R4、R8和Ra是指定的有机基团，n和p独立地为0、1、2、3或4；或其盐或N-氧化物或含有它们的组合物在控制昆虫、螨虫、线虫或软体动物方面也提供了新型化合物。
• (4-Phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone Compounds and Their Use
  申请人：Webster Scott Peter

  公开号：US20120172393A1

  公开（公告）日：2012-07-05

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

  本发明涉及治疗化合物领域。更具体地说，本发明涉及某些(4-苯基哌啶-1-基)-[5-(1H-吡唑-4-基)-噻吩-3-基]-甲酮化合物，其中包括抑制11β-羟化类固醇脱氢酶1型(11β-HSD1)的化合物。本发明还涉及包含此类化合物的制药组合物的使用，以及在体外和体内使用此类化合物和组合物以抑制11β-羟化类固醇脱氢酶1型；治疗由抑制11β-羟化类固醇脱氢酶1型改善的疾病；治疗代谢综合征，包括2型糖尿病和肥胖症等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质代谢异常和心血管疾病，如缺血性(冠状)心脏病；治疗轻度认知障碍和早期痴呆等中枢神经系统疾病，包括阿尔茨海默病等。
• CHEMICAL COMPOUNDS
  申请人：Maienfisch Peter

  公开号：US20120270885A1

  公开（公告）日：2012-10-25

  The use of a compound of formula I Y is a single bond, C═O, C═S or S(O) m where m is 0, 1 or 2; the ring is a 6 membered aromatic ring or is a 5 or 6 membered heteroaromatic ring; Z and Z′ are provided that both are not N; R 1 , R 2 , R 3 , R 3a , R 4 , R 8 and Ra are specified organic groups and n and p are independently 0, 1, 2, 3 or 4; or salts or N-oxides thereof or compositions containing them in controlling insects, acarines, nematodes or molluscs. Novel compounds are also provided.

  公式IY的化合物的使用是指单键，C═O，C═S或S(O)m，其中m为0、1或2；环是6元芳香环或5或6元杂环；Z和Z′是提供的，只要两者都不是N；R1、R2，R3，R3a，R4，R8和Ra是指定的有机基团，n和p是独立的0、1、2、3或4；或其盐或N-氧化物或含有它们的组合物在控制昆虫、螨、线虫或软体动物方面提供了新的化合物。